Cantor Fitzgerald Estimates Disc Medicine FY2026 Earnings

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Disc Medicine in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($5.46) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $132.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Several other equities analysts also recently weighed in on IRON. Scotiabank increased their target price on Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. BMO Capital Markets increased their target price on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Morgan Stanley reissued an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. Finally, TD Cowen began coverage on Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating for the company. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and an average price target of $98.80.

Disc Medicine Stock Up 3.2%

Shares of IRON traded up $1.65 on Tuesday, hitting $53.07. 359,027 shares of the stock traded hands, compared to its average volume of 348,170. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $68.73. The stock's 50 day moving average is $44.86 and its two-hundred day moving average is $53.51. The firm has a market capitalization of $1.84 billion, a P/E ratio of -13.33 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03).

Insider Activity at Disc Medicine

In other news, Director Mona Ashiya sold 83,182 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $54.45, for a total transaction of $4,529,259.90. Following the completion of the transaction, the director now directly owns 194,209 shares in the company, valued at approximately $10,574,680.05. This represents a 29.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the company's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the sale, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 150,360 shares of company stock valued at $8,111,828. Insiders own 4.24% of the company's stock.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently bought and sold shares of IRON. Rhumbline Advisers grew its position in shares of Disc Medicine by 10.7% in the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company's stock worth $1,596,000 after acquiring an additional 3,108 shares in the last quarter. Strs Ohio bought a new position in Disc Medicine during the first quarter worth $347,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock worth $4,793,000 after purchasing an additional 3,454 shares during the period. Woodline Partners LP boosted its holdings in Disc Medicine by 26.6% in the first quarter. Woodline Partners LP now owns 502,230 shares of the company's stock worth $24,931,000 after purchasing an additional 105,630 shares during the period. Finally, Zimmer Partners LP increased its stake in Disc Medicine by 29.6% during the first quarter. Zimmer Partners LP now owns 42,900 shares of the company's stock valued at $2,130,000 after purchasing an additional 9,800 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.